This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Levonorgestrel oral 1500mcg

Updated 2 Feb 2023 | Emergency contraception


Tablets containing 1500 micrograms levonorgestrel.

Drugs List

  • EMERRES 1.5mg tablets
  • EMERRES UNA 1.5mg tablets
  • EZINELLE 1.5mg tablets
  • LEVONELLE 1500microgram tablets
  • levonorgestrel 1500microgram tablets
  • MELKINE 1.5mg tablets
  • POSTINOR 1500microgram tablets
  • UPOSTELLE 1500microgram tablets
  • Therapeutic Indications


    Emergency contraception - post-coital (within 72 hours of intercourse)


    Levonorgestrel may be taken at any time during the menstrual cycle, except when menstrual bleeding is overdue.


    A single dose of 1500 micrograms to be taken preferably within 12 hours and no later than 72 hours after unprotected sexual intercourse.

    If vomiting occurs with three hours of taking the tablet, another tablet should be taken immediately.

    Unlicensed dose
    In patients weighing over 70kg or have a BMI greater than 26kg/metre squared consider higher dose of levonorgestrel 3000 micrograms.

    Additional Dosage Information

    Concomitant use of hepatic enzyme inducers (particularly CYP3A4 enzyme inducers) results in the increased metabolism of levonorgestrel. This may reduce emergency contraceptive efficacy. The elevated levels of CYP3A4 enzymes can persist for 4 weeks after the discontinuation of the enzyme inducing medicine.

    Females seeking emergency contraception, who have used CYP3A4 enzyme inducers in the last 4 weeks, should use a non-hormonal emergency contraceptive (for example a copper intrauterine device). However, if this is not an option, double the usual dose of levonorgestrel to 3000 micrograms.


    History of ectopic pregnancy
    History of salpingitis
    Severe hepatic impairment

    Precautions and Warnings

    Children under 16 years
    Gastrointestinal hypermotility
    Glucose-galactose malabsorption syndrome
    Lactose intolerance
    Malabsorption syndrome

    Patients weighing over 70kg or with BMI over 26kg/m2: Consider higher dose
    Contains lactose
    Repeated use within one menstrual cycle is not advisable
    Treatment is ineffective more than 72 hours after unprotected intercourse
    Exclude pregnancy prior to initiation of treatment
    If pregnancy occurs possibility of ectopic pregnancy should be considered
    Advise patient to consult doctor if lower abdominal pain occurs
    Advise patient to consult doctor if menstruation overdue >5 days/ abnormal
    Vomiting or severe diarrhoea may impair efficacy
    Advise patient not to take St John's wort concurrently
    Female: Barrier contraception recommended for the rest of the monthly cycle
    Advise patient early or late onset of next menstrual period is possible
    Take another dose if vomiting occurs within 3 hours
    Treatment does not protect against risk of sexually transmitted disease

    Pregnancy and Lactation


    Levonorgestrel is contraindicated in pregnancy.

    The manufacturer advises that levonorgestrel should not be given to pregnant women. Levonorgestrel will not interrupt a pregnancy. Limited epidemiological data indicates that there are no adverse effects on the foetus from Levonorgestrel use during pregnancy. However there is limited clinical data on doses greater than 1500 micrograms.


    Use levonorgestrel with caution in breastfeeding.

    The manufacturers advises potential exposure of the infant can be reduced by taking the tablets immediately after breastfeeding, and not breastfeeding for 8 hours after the tablets are taken. Levonorgestrel is secreted in breast milk, it has been indicated that this does not affect the composition of milk, the growth and development of the infant or the milk supply.


    If vomiting occurs within 3 hours of taking the tablets, a further 1500 micrograms should be taken immediately. The patient should be advised to contact her doctor, family planning clinic or pharmacist for advice and more tablets.

    Patients should be advised that after taking levonorgestrel, barrier methods of contraception should be adopted until the next menstrual period begins.

    Patients should be advised that their next period may be early or late.

    If menstrual bleeding is overdue by more than 5 days, or abnormal bleeding occurs (e.g. abnormally light, heavy or brief) at the normal time of menstruation, or pregnancy is suspected for any other reason, a doctor should be consulted so that pregnancy may be ruled out.

    Patients should be advised to consult their doctor if lower abdominal pain occurs, as this could indicate an ectopic pregnancy.

    Women who repeatedly request emergency contraception should be advised to consider a conventional regular method of contraception.

    Patients purchasing levonorgestrel should be advised to seek medical advice if taking any other drugs, including herbal remedies such as St John's Wort.

    Side Effects

    Breast tenderness
    Facial oedema
    Irregular uterine bleeding
    Lower abdominal pain
    Menstrual disturbances
    Pelvic pain
    Vaginal bleeding


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: June 2015

    Reference Sources

    Summary of Product Characteristics: Emergency contraceptive consilient 1500 microgram tablet. Consilient Health Ltd. Revised April 2017.
    Summary of Product Characteristics: Emerres 1.5 mg tablet. Morningside Healthcare Ltd. Revised March 2018.
    Summary of Product Characteristics: Emerres Una 1.5 mg tablet. Morningside Healthcare Ltd. Revised December 2017.
    Summary of Product Characteristics: Ezinelle 1.5 mg tablet. Mylan Ltd. Revised October April 2017.
    Summary of Product Characteristics: Levonelle tablets 1500mcg. Bayer plc. Revised March 2018.
    Summary of Product Characteristics: Levonelle One Step. Bayer plc. Revised June 2020.
    Summary of Product Characteristics: Melkine 1.5mg tablets. Crescent Pharma Ltd. Revised December 2016.
    Summary of Product Characteristics: Postinor 1500 microgram tablet. Gedeon Richter (UK) Ltd. Revised May 2021.
    Summary of Product Characteristics: Upostelle 1500 microgram tablet. Consilient Health Ltd. Revised January 2017.

    NICE Evidence Services Available at: Last accessed: 05 August 2022

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Levonogrestrel Last revised: 18 July 2022
    Last accessed: 05 August 2022

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.